EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Clinical trials for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) trials appear
Sign up with your email to follow new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for aggressive lung cancer: experimental drug combo enters late-stage trial
Disease control Recruiting nowThis study tests whether adding an experimental drug called obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combi…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
New triple therapy targets stubborn lung cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug (iadademstat) combined with targeted radiation and an immunotherapy (atezolizumab) in people with extensive-stage small-cell lung cancer that didn't fully respond to initial chemotherapy. The main goal is to check safety and find the right …
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Ab…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC